Smoking-ban backers, opponents vow to keep battling
Supporters of a stricter ban on smoking in Indianapolis workplaces said the City-County Council’s decision Monday night to table the proposal will not kill efforts to get legislation passed.
Health Care & Life Sciences
Articles
Council tables smoking ban
Efforts to broaden Indianapolis’ workplace smoking ban came up short Monday night as members of the City-County Council voted
to table the proposal. The ordinance would have prohibited patrons from lighting up in bars, bowling alleys and nightclubs,
expanding an existing law that prohibits smoking in most public places, including restaurants that serve minors.
Lilly to move 1,000 from Faris campus
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate
center
by mid-2010.
Indy Chamber of Commerce endorses smoking ban
The Indianapolis Chamber of Commerce is throwing its weight behind a tougher workplace smoking ban up for consideration tonight
by the City-County Council.
Lilly settles Zyprexa case with S. Carolina for $45M
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker
Eli Lilly and Co. over the company’s marketing of an anti-psychotic drug.
Burst pipe halts surgeries at Wishard Hospital
Wishard Memorial Hospital in Indianapolis closed its main operating rooms and canceled at least 15 surgeries Friday after
a steam pipe burst. Hospital officials say the burst pipe is an example of the infrastructure problems that are prompting
plans for a new facility.
Experts: Feds’ antitrust move poses few risks to health insurers
Democratic lawmakers are seeking to stir up competition by stripping health insurers like Indianapolis-based WellPoint of
their protection from certain federal antitrust laws, although experts shrug off the effort as largely symbolic.
Indianapolis-based FAST Diagnostics gets funding from BioCrossroads’ seed fund
Money will help the company refine its tool to treat acute kidney injury.
Gregory & Appel celebrates anniversary by writing 125 checks to charity
The awards of $500 each total $62,500. “In lieu of doing a party, it was more
appropriate and more the corporate culture of Gregory & Appel to do something charitable,”
Vice President Steve Appel said.
Cook Group Inc. owner says health reform’s tax on medical devices could kill jobs
Bloomington-based Cook Group Inc. might have to cut as many as 1,000 local jobs if Congress enacts a tax on medical devices
to pay for health care reform, company founder Bill Cook said in an interview.
Lilly needs to sell more Effient before Zyprexa loses patent protection
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
Eli Lilly CEO banking on new drug pipeline
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.
Zimmer profits fall, but beat expectations
The Warsaw-based company recorded a third-quarter profit of $150 million, down 30 percent from the same quarter a year ago.
Goodwill executive to lead national health care board
Goodwill Industries executive Keith Reissaus has been tapped to run Washington, D.C.-based Leapfrog Group, an industry coalition.
Reissaus gained control of health care costs by giving employees incentives to care about their health.
Indiana insurance industry weathers hard times
Employment in Indiana’s insurance industry has remained stable despite a poor economy.
Lilly, GE announce cancer diagnostic breakthrough
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Uncertainty over drug pipeline sends Lilly shares down
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren’t likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
Democrats eye insurance industry’s antitrust protection
Top Senate Democrats intend to try to strip the health insurance industry of its exemption from federal antitrust laws, according
to congressional officials, the latest evidence of a deepening struggle over President Barack Obama’s effort to overhaul the
health care industry.
Bristol-Myers Squibb plans 113 job cuts in southern Indiana
Drugmaker Bristol-Myers Squibb Co. plans to close one of its southern Indiana facilities and cut jobs at another.
Lilly reports $942 million profit in third quarter
Excluding special items, Eli Lilly and Co.’s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly’s revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.